Kamil Kouřil

• Fundraising, Key Accounts Management, Projects preparation & management, Policy recommendations preparation (Public Health)
• Demonstrated strong organizational and time management skills while managing multiple projects.
• Demonstrated leadership skills in managing projects from concept to completion.
• Participated in team projects, demonstrating ability to work collaboratively and effectively
• Excellent communication skills, both verbal and written
• Demonstrated strong organizational and time management skills while managing multiple projects
• Developed strong communication and organizational skills through working on group projects

• Negotiated and closed long-term agreements and cooperation with new clients within EU/worldwide.
• Generated new business with marketing initiatives and strategic plans.
• Reached out to existing and potential customers via telephone, email, and in-person inquiries.
• Established relationships with key decision-makers within customer's organization to promote growth and retention.
• Identified and pursued valuable business opportunities to generate new company revenue and improve bottom line profit.
• Built relationships with customers and community to establish long-term business growth.

Sales & Marketing responsibility for cardiovascular medical devices (implantable IPGs, ICDs, CRTDs, ICMs, electrophysiology) :

• Managing sales & marketing within existing accounts, cooperation with distributors, target settings, forecasting, reporting
• Securing appropriate market access conditions/regulatory in dedicated area of products responsibility
• Tenders follow ups, Managing Distributors
• Securing continuous medical education „Hands On Trainings“
• Direct supervision of 5 Sales reps/technicians; Budget responsibility 1500k €, planning and execution of marketing projects,
• Annual Sales budget resp. 7mil. € (annual turnover), full P&L and market access/entry responsibility
• Successfully managed budgets and allocated resources to maximize productivity and profitability.
• Recruited, interviewed and hired employees and implemented mentoring program to promote positive feedback and engagement.
• Evaluated employee performance and conveyed constructive feedback to improve skills.
• Developed detailed plans based on broad guidance and direction.

General management of 1 Business Franchise – Dermatology & Immunology (Company Board Member) :

• Whole P&L, A&P responsibility (launching specialty Rx products in dermatology: Cosentyx-Secukinumab, Xolair-Omalizumab in CSU-urticaria, transplant portfolio)
• Direct Management of 4 KAMs, 1 Brand Manager, Assistant
• Evaluated market data to develop and create business strategies and marketing plans.
• Suggested innovative ideas to increase sales and improve customer experience.
• Analyzed and forecasted monthly sales data of existing marketed specialty products within designated area.
• Cultivated and maintained strategic alliances with key partners and vendors.
• Managed production of leaflets, posters and newsletters.
• Created and implemented effective marketing and sales strategies to increase customer engagement and revenue.
• Evaluated and monitored promotional activities to confirm adequate return on promotional funds.
• Conducted market research to identify new opportunities and target markets.

Marketing responsibility for Onco/Oncohematology area :

• Specialty Rx products (MOABs) with total annual turnover above 12 mil. €
• Oncohematology: Mabthera-Rituximab, Gazyvaro
• Oncology: Zelboraf-Vemurafenib, Herceptin-Trastuzumab, Perjeta-Pertuzumab)
• Coordinated project planning and execution with team members and team leads.
• Collaborated with sales, marketing, and support teams to launch products on time and within budget.
• Liaised with clients to better understand business needs and current market landscape.
• Monitored market trends and competitor performance to update promotional strategies.
• Directed planning and budgeting efforts.

Marketing & sales responsibility for :

• Specialty RX products with total annual turnover above 4 mil. € (Oncology: Tyverb-Lapatinib, Votrient-Pazopanib, Haematatology: Revolode, Arzerra)